Intensity Therapeutics (INTS) CEO receives 37,749-share stock bonus grant

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

BENDER LEWIS H reported acquisition or exercise transactions in this Form 4 filing.

INTENSITY THERAPEUTICS, INC. President and CEO Lewis H. Bender received a grant of 37,749 shares of common stock at $6.11 per share as a fully vested stock award under the company’s 2021 Stock Incentive Plan. The award was made in partial satisfaction of his 2025 bonus, in lieu of cash, at his request. Following this grant, he holds 118,549 common shares directly, with all amounts adjusted for a 1-for-25 reverse stock split effected on February 18, 2026.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BENDER LEWIS H

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, $0.0001 Par Value	37,749	$6.11	$231K

Holdings After Transaction: Common Stock, $0.0001 Par Value — 118,549 shares (Direct)

Footnotes (1)

Granted to the Reporting Person as a fully vested stock award under the Issuer's 2021 Stock Incentive Plan in partial satisfaction of the 2025 bonus payment to the Reporting Person in lieu of cash, at the Reporting Person's request. On February 18, 2026, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, all amounts of securities reported in this Form 4 have been adjusted to reflect the 1-for-25 reverse split.

Key Figures

Stock award size: 37,749 shares Award valuation price: $6.11 per share Post-transaction holdings: 118,549 shares +1 more

4 metrics

Stock award size 37,749 shares Fully vested stock award for 2025 bonus

Award valuation price $6.11 per share Value used for bonus stock in lieu of cash

Post-transaction holdings 118,549 shares Common stock held directly after grant

Reverse split ratio 1-for-25 Common stock reverse split on February 18, 2026

Key Terms

fully vested stock award, 2021 Stock Incentive Plan, 1-for-25 reverse split, in lieu of cash

4 terms

fully vested stock award financial

"Granted to the Reporting Person as a fully vested stock award under the Issuer's 2021 Stock Incentive Plan"

2021 Stock Incentive Plan financial

"under the Issuer's 2021 Stock Incentive Plan in partial satisfaction of the 2025 bonus payment"

1-for-25 reverse split financial

"the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock"

in lieu of cash financial

"in partial satisfaction of the 2025 bonus payment to the Reporting Person in lieu of cash, at the Reporting Person's request"

Form 4 Insider Transactions: What Each Field Means →

03/30/2026 - 05:29 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BENDER LEWIS H

(Last)

(First)

(Middle)

C/O INTENSITY THERAPEUTICS, INC.

1 ENTERPRISE DRIVE, SUITE 430

(Street)

SHELTON

CONNECTICUT

06484

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INTENSITY THERAPEUTICS, INC. [ INTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, $0.0001 Par Value	03/26/2026	03/26/2026	A		37,749⁽¹⁾	A	$6.11	118,549⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Granted to the Reporting Person as a fully vested stock award under the Issuer's 2021 Stock Incentive Plan in partial satisfaction of the 2025 bonus payment to the Reporting Person in lieu of cash, at the Reporting Person's request.

2. On February 18, 2026, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, all amounts of securities reported in this Form 4 have been adjusted to reflect the 1-for-25 reverse split.

Remarks:

	/s/ Kostantinos Skordalos, Attorney-in-fact	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Intensity Therapeutics (INTS) report for Lewis H. Bender?

Lewis H. Bender received 37,749 shares of Intensity Therapeutics common stock as a fully vested stock award. The shares were granted under the 2021 Stock Incentive Plan as part of his 2025 bonus compensation, replacing a portion of cash bonus at his request.

At what price was the Intensity Therapeutics (INTS) stock award valued?

The stock award to Lewis H. Bender was valued at $6.11 per share. This per-share value is used to determine the share amount granted in lieu of a portion of his 2025 cash bonus, under the company’s 2021 Stock Incentive Plan.

How many Intensity Therapeutics (INTS) shares does Lewis H. Bender hold after this grant?

After the stock award, Lewis H. Bender directly holds 118,549 shares of Intensity Therapeutics common stock. This total reflects the new grant of 37,749 shares and incorporates adjustments from the company’s 1-for-25 reverse stock split in February 2026.

Was the Intensity Therapeutics (INTS) CEO stock grant part of his bonus?

Yes. The 37,749-share stock award to Lewis H. Bender was granted in partial satisfaction of his 2025 bonus. It was provided in lieu of cash, at his request, under Intensity Therapeutics’ 2021 Stock Incentive Plan as fully vested common stock.

How did Intensity Therapeutics’ 1-for-25 reverse split affect this Form 4?

The company’s 1-for-25 reverse split on February 18, 2026 reduced outstanding share counts and adjusted equity awards proportionately. All share amounts reported in this Form 4, including the 37,749-share grant and 118,549 total holdings, are already adjusted for that reverse split.

Is the Intensity Therapeutics (INTS) CEO stock award a market purchase or compensation grant?

The transaction is a compensation grant, not a market purchase. Lewis H. Bender received 37,749 fully vested shares as a stock award under the 2021 Stock Incentive Plan, issued as part of his 2025 bonus instead of receiving that portion in cash.